Every year the FTC brings hundreds of cases against individuals and companies for violating consumer protection and competition laws that the agency enforces. These cases can involve fraud, scams, identity theft, false advertising, privacy violations, anti-competitive behavior and more. The Legal Library has detailed information about cases we have brought in federal court or through our internal administrative process, called an adjudicative proceeding.
In re: Proxim Corporation, et al., Debtors
Occidental Petroleum Corporation and Vulcan Materials Company, In the Matter of
Entergy Corporation and Entergy-Koch, LP
A consent order settles allegations that Entergy-Koch LP's (a limited partnership owned equally by Entergy Corporation and Koch) acquisition of 50 percent of the Gulf South Pipeline Company, LP from Koch would lessen competition for the sale of electricity to consumers in Louisiana and western Mississippi and the distribution of natural gas to consumers in New Orleans and Baton Rouge. Entergy is the regulated electric and natural gas utility in parts of Louisiana and Mississippi. The order requires Entergy to establish a transparent process to buy natural gas and natural gas transportation that will assist state regulators in determining whether Entergy purchased gas supplies at inflated prices from its Entergy-Koch partnership.
Iworx, a corporation, and Selfworx.com, LLC, and Jeffrey V. Kral
Hi-Health Supermart Corporation and Simon D. Chalpin, In the Matter of
Proposed Acquisition of Nassda Corporation by Synopsys Inc.
Bikini Vending Corp., a Nevada corporation, et al.
Capital City Mortgage Corporation, A Maryland Corporation; et. al
American Merchant Technologies, Inc., a Florida Corporation, et al., US v.
Flagship Resort Development Corporation, a New Jersey Corporation and Atlantic Palace Development, LLC, a New Jersey limited liability corporation
Genzyme Corporation and Ilex Oncology, Inc., In the Matter of
A consent order allowed Genzyme’s acquisition of ILEX Oncology, Inc., but requires the companies to divest certain assets in the market for solid organ transplant acute therapy drugs. Specifically, Genzyme is required to divest all contractual rights related to ILEX’s Campath®, an immunosuppressant antibody used in solid organ transplants to Schering AG.